2 results
Approved WMOCompleted
To determine the safety and efficacy of Dimebon in patients with mild-to-moderate Huntington Disease
Approved WMORecruiting
Primary objective:• To evaluate the efficacy of luspatercept on RBC transfusion independence (RBC-TI for 12 weeks [84 days] with an associated concurrent mean hemoglobin increase >= 1.5 g/dL) compared with epoetin alfa for the treatment of…